Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | CDC25A | P30304 | 2/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 9/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13852396 | 1.00 | CYP19A1 (0.49) | CYP19A1CDC25ACDC25BVDRHDAC6 | |
| SCHEMBL12464968 | 1.00 | CYP19A1 (0.49) | CYP19A1CDC25ACDC25BVDRHDAC6 | |
| SCHEMBL13669231 | 1.00 | CYP19A1 (0.49) | CYP19A1CDC25ACDC25BVDRHDAC6 | |
| SCHEMBL10125598 | 0.84 | CDC25A (0.46) | CYP19A1CDC25ACDC25BVDRHDAC6 | |
| SCHEMBL814645 | 0.84 | CDC25A (0.46) | CYP19A1CDC25ACDC25BVDRHDAC6 | |
| SCHEMBL17354893 | 0.84 | CYP19A1 (0.45) | CYP19A1CDC25ACDC25BVDRHDAC6 | |
| SCHEMBL3516877 | 0.84 | CYP19A1 (0.45) | CYP19A1CDC25ACDC25BVDRHDAC6 | |
| SCHEMBL3516879 | 0.84 | CYP19A1 (0.45) | CYP19A1CDC25ACDC25BVDRHDAC6 | |
| SCHEMBL9010563 | 0.84 | CYP19A1 (0.45) | CYP19A1CDC25ACDC25BVDRHDAC6 | |
| SCHEMBL20243735 | 0.84 | CYP19A1 (0.45) | CYP19A1CDC25ACDC25BVDRHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377913-B2 | Vitamin D receptor activators and methods of making | ABBVIE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2007038094-A1 | 19,23,24,25,26,27-HEXANOR-1ALPHA-HYDROXYVITAMIN D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070066566-A1 | 19,23,24,25,26,27-Hexanor-1alpha-hydroxyvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066566-A1 | 19,23,24,25,26,27-Hexanor-1alpha-hydroxyvitamin D3 | CYP24A1, CYP2R1, CYP27B1 | CYP19A1 27/4885CDC25A 1079/4885CDC25B 1851/4885 |
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | VDR, CYP2R1, CYP24A1 | CYP19A1 40/4885CDC25A 2827/4885CDC25B 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.